TABLE 1.
Cohort demographics and clinical information.
| Variablea | CRSsNPb (n = 77) | CRSwNPb (n = 79) | Disease controlb (n = 45) | Healthy controlb (n = 35) | Unadjusted p-valuec |
| Age | 46 (19 to 77) | 46 (18 to 75) | 45 (19 to 82) | 24 (20 to 55) | <0.001 |
| Gender | 38 of 77 (49%) | 53 of 79 (67%) | 29 of 45 (64%) | 16 of 35 (45%) | 0.007 |
| European | 69 of 77 (90%) | 65 of 79 (82%) | 37 of 45 (82%) | 20 of 35 (57%) | <0.001 |
| Smoker | 2 of 73 (3%) | 7 of 77 (9%) | 4 of 45 (9%) | 0 of 35 (0%) | 0.011 |
| Asthma | 30 of 69 (43%) | 42 of 72 (65%) | 6 of 43 (14%) | NA | <0.001 |
| Medication information | |||||
| Antibiotic usage (1 year prior to sample collection) | 61 of 76 (80%) | 52 of 74 (70%) | 38 of 45 (84%) | 8 of 35 (23%) | <0.001 |
| Antibiotic usage (1 month prior to sample collection) | 4 of 77 (5%) | 11 of 78 (13%) | 0 of 45 (0%) | 0 of 35 (0%) | 0.009 |
| Number of antibiotics (tablets) | 57 (0 to 654) | 26 (0 to 397) | 48 (0 to 189) | NA | 0.03 |
| Number of antibiotic courses | 1 (0 to 12) | 1 (0 to 8) | 2 (0 to 4) | NA | 0.178 |
| Heavy antibiotic usersd | 13 of 72 (18%) | 5 of 69 (7.2%) | 2 of 39 (5%) | 0 of 35 (0%) | <0.001 |
| Patient outcomes | |||||
| Lund-Mackay score | n = 70 13 (5 to 22) | n = 72 19 (6 to 24) | n = 26 0 (0 to 4) | NA | <0.001 |
| SNOT-22 score | n = 35 39 (4 to 85) | n = 33 36 (3 to 94) | n = 14 14 (0 to 57) | NA | <0.001 |
aCategorical variables are summarized as proportion yes/total (%), except for gender, which is given as proportion female. Continuous variables are summarized as median (range).
bTotal cohort numbers for each group are given. Differences in total numbers for each variable reflect missing data from some subjects.
cOverall differences between groups were tested using Chi-squared test or Fisher’s exact test (for groups with n < 5) for categorical variables and ANOVA or Kruskal-Wallis test (for non-normally distributed data) for continuous variables. Significant p-values of interest (p < 0.05) are noted in bold.
dHeavy antibiotic users are subjects that received more than 150 tablets throughout the one-year period. SNOT-22, 22 item sinonasal outcome test; CRSsNP, CRS without nasal polyps; CRSwNP, CRS with nasal polyps; NA, not available.